2026-05-13 · 2026-05 / week-1

BD Still Trades Headline EPS, Not New BD

BD Still Trades Headline EPS, Not New BD

Summary: BDX last traded at $144.41 at 00:13 Singapore time on May 14, 2026. On May 7, 2026, Becton, Dickinson reported second-quarter continuing-operations revenue of $4.714 billion, adjusted diluted EPS of $2.90, and raised fiscal 2026 adjusted EPS guidance to $12.52 to $12.72. Yet the stock still screens like a litigation-heavy, separation-distorted mess. Against BD's own updated guide, the same price is only about 11.4x forward adjusted EPS.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 BD still trades headline EPS, not New BD U.S. large-cap medtech / post-spin reset / capital return BDX last traded at $144.41 after BD raised fiscal 2026 adjusted EPS guidance to $12.52 to $12.72, reported second-quarter adjusted diluted EPS of $2.90, and disclosed 11.513 million shares still authorized for repurchase after a $2.0 billion ASR. Official May 7, 2026 results, March 31, 2026 10-Q, and a live May 14, 2026 Singapore-time market snapshot. Final ASR settlement is due in fiscal Q3 2026, the share count keeps shrinking, and each new quarter makes the continuing-operations earnings base cleaner. The tape still reflects dirty GAAP optics and legal noise, while the post-spin company now trades closer to a low-teens medtech multiple on management's own guide. Product remediation and litigation can stay noisy longer than value investors expect.
2 Nomura still trades as a broker, not a 10% ROE capital-return story Japan financial / below-book rerating / buyback NMR last traded at $8.10 after Nomura reported record full-year net income of JPY 362.1 billion, 10.1% ROE, a JPY 51 annual dividend, and a JPY 60 billion buyback authorization. Official April 24 and January 30, 2026 releases plus a live May 14, 2026 Singapore-time market snapshot. Ongoing buyback execution and quarterly follow-through. Capital return is real and the valuation is still undemanding. The closing mechanism is slower and the main positive surprise has already printed.
3 Baidu still trades the China discount, not the return stack Broader Asia / China ADR / capital return / AI transition BIDU last traded at $149.63 after Baidu announced a new $5.0 billion repurchase program, its first regular dividend policy, and set May 21, 2026 for first-quarter results. Official February 26 and April 23, 2026 releases plus a live May 14, 2026 Singapore-time market snapshot. Q1 results on May 21, 2026 and later dividend execution. The return package is large and the event calendar is close. The valuation bridge still carries heavier governance and macro inference than the best idea today.
4 RELX keeps shrinking the float, but the market already pays for it Europe / UK quality compounder / active buyback RELX last traded at $31.47 after reporting 128.5p adjusted EPS, a 67.5p dividend, and a planned GBP 2.25 billion 2026 buyback, with GBP 250 million already completed when it reaffirmed outlook on April 23. Official February 12 and April 23, 2026 company releases plus a live May 14, 2026 Singapore-time market snapshot. Ongoing buyback execution and first-half 2026 results. The share-count math is real. The business is excellent, but the market already assigns a premium multiple to that quality.

Selected opportunity: BD still trades headline EPS, not New BD.

Why this one now: It has the cleanest mix of fresh primary evidence, a live capital-return mechanism, visible accounting simplification, and enough liquidity to matter to real investors.

What should surprise the reader: A sophisticated reader should not still be looking at BD as a messy earnings screen when the company has already simplified itself, raised the forward guide, retired a large block of stock, and still has buyback capacity equal to about 4.2% of the April 30 share count.

Geographic Search Audit

  • U.S. candidate screened: BD. Selected.
  • Japan candidate screened: Nomura. Real rerating case, but the timing is slower.
  • Broader Asia candidate screened: Baidu. Real capital return, but more inference load.
  • Europe / UK candidate screened: RELX. High quality, but less disagreement.
  • If any lane was rejected, why: Japan lost on urgency, broader Asia lost on governance and macro discount complexity, and Europe / UK lost on surprise potential.

Why This Is the Best Opportunity Right Now

The best mispricings are often optical before they are narrative. BD is one of those cases.

This stock still looks untidy on headline numbers because the business spent the quarter finishing a major portfolio reset, retiring debt, running a large accelerated repurchase, and absorbing the usual separation, restructuring, legal, and remediation noise. The market can see all that noise. It is slower to capitalize what sits underneath it.

What sits underneath it is simpler. BD now reports a cleaner continuing-operations medtech base, raised its full-year adjusted EPS guide, already delivered the initial block of a $2.0 billion ASR, and still has repurchase authority with no expiration. That is a more concrete closing mechanism than a vague rerating hope.

What Should Surprise the Reader

The surprise is not that BD is buying back stock. Large medtech companies do that all the time.

The surprise is the valuation frame. The same stock that looks optically expensive on a trailing screen is only about 11.4x BD's updated fiscal 2026 adjusted EPS midpoint. That is before giving credit for a still-open buyback authorization equal to roughly 11.513 million shares, or about 4.2% of the April 30 share count. [Sources: BD Q2 fiscal 2026 results, BD March 31, 2026 10-Q, OpenAI finance snapshot.]

The Setup

On February 9, 2026, BD completed the combination of its Biosciences and Diagnostic Solutions business with Waters. BD said the transaction delivered about $4.0 billion of net cash proceeds at closing and a 39.2% ownership stake in Waters. [Source: BD transaction-close release.]

It did not sit on the cash. The company entered a $2.0 billion ASR on January 30, 2026, received an initial delivery of 9,319,664 shares in fiscal Q2, and said the final settlement will occur in fiscal Q3 2026 based on the average market price during the purchase period, less a discount. BD's financing cash flows also show about $2.0 billion of debt payments in the first half. [Source: BD March 31, 2026 10-Q.]

Then came the cleaner operating evidence. On May 7, 2026, BD reported second-quarter continuing-operations revenue of $4.714 billion, up 5.2% as reported and 2.6% currency-neutral. Adjusted diluted EPS from continuing operations was $2.90, up 10.7% as reported and 7.0% currency-neutral. Management raised fiscal 2026 adjusted EPS guidance to $12.52 to $12.72 from $12.25 to $12.40 and reiterated 3.0% to 4.0% organic revenue growth. [Source: BD Q2 fiscal 2026 results.]

The headline GAAP picture still looked ugly. BD reported a loss from continuing operations of $311 million and a diluted loss per share from continuing operations of $1.11 in the quarter. Its 10-Q reconciliation shows $1.448 billion of first-half specified items between reported and adjusted earnings, including purchase accounting, integration, restructuring, transaction, separation, product-remediation, legal, pension-settlement, and debt-extinguishment items. [Sources: BD Q2 fiscal 2026 results, BD March 31, 2026 10-Q.]

The Market Price

BDX last traded at $144.41 at 00:13 Singapore time on May 14, 2026. The OpenAI finance snapshot showed a market capitalization of about $39.77 billion and a trailing P/E of about 36.6x.

That trailing multiple is the wrong lens. Against BD's updated fiscal 2026 adjusted EPS midpoint of $12.62, the stock trades at only about 11.4x forward adjusted EPS.

The share-count math is also less appreciated than it should be:

  • BD repurchased 1,315,183 shares for $250 million in fiscal Q1.
  • The initial ASR delivery added another 9,319,664 repurchased shares in fiscal Q2.
  • As of March 31, 2026, BD still had authorization to repurchase 11,513,362 additional shares with no expiration.
  • As of April 30, 2026, BD had 275,540,427 shares outstanding, so the remaining authorization equals about 4.2% of that share count.
  • At today's stock price, that remaining authorization is worth roughly $1.66 billion.

This is not a vague future promise. BD has already taken about 3.9% of the April 30 share count out through open-market repurchases and the initial ASR delivery, with more to come when the ASR settles and if the board uses the remaining authorization. [Source: BD March 31, 2026 10-Q.]

The Positioning

I did not verify live short interest, borrow cost, or options positioning during this run.

So the positioning case here is inferential, not measured. The market still appears to treat BD as a cluttered legal-and-remediation story because the reported numbers are still carrying separation and clean-up charges. That is exactly why the opportunity exists. This is less a squeeze setup than a stale-categorization setup.

Missing-data note: direct holder-flow evidence was weaker than the accounting, guidance, and share-count evidence in this run.

The Catalyst

The catalyst path is not a single binary date. It is a sequence.

  1. The ASR's final settlement arrives in fiscal Q3 2026, which should deliver the final share count from the already committed $2.0 billion repurchase.
  2. Each subsequent quarter reports more of BD as a cleaner continuing-operations medtech company and less as a portfolio in transition.
  3. The raised fiscal 2026 adjusted EPS guide gives the market a valuation anchor that is harder to dismiss than story stock optimism.
  4. The remaining 11.513 million share authorization gives management a continuing mechanical way to close part of the valuation gap.

The closing mechanism is simple: the denominator falls, the accounting noise fades, and the market has fewer excuses to value BD off distorted trailing figures.

The Gap

Facts: BD completed the Waters combination, received about $4.0 billion of net cash, ran a $2.0 billion ASR, lifted adjusted EPS guidance to $12.52 to $12.72, and still has authorization to buy back about 4.2% of the April 30 share count. [Sources: BD transaction-close release, BD Q2 fiscal 2026 results, BD March 31, 2026 10-Q.]

Inference: The stock is still being valued too heavily through the lens of dirty headline earnings and legal-product-remediation noise rather than through the lens of a simpler post-spin medtech base with active denominator shrink.

Speculation: If management keeps hitting the continuing-operations guide and the litigation or remediation narrative does not deteriorate, the market can plausibly rerate BD back toward a more normal medtech earnings multiple over the next 6 to 12 months.

Trade expression: The cleanest expression is long BDX common stock. Options are secondary only if a live chain later proves liquid and rationally priced.

The Payoff Map

This is not a heroic upside case. It does not need to be.

At today's price, the thesis only needs the market to stop using the wrong denominator and to recognize that BD is now retiring stock while reporting a cleaner forward earnings base. The downside is real, because litigation and remediation stories can stay sticky. The upside is that the rerating bar is low.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 30% BDX $175.00 +21.2% 6-12 months The ASR settles favorably, BD keeps delivering against the raised guide, specified items stop dominating the narrative, and the stock rerates toward a cleaner medtech multiple. Medium
Base Case 50% BDX $160.00 +10.8% 3-9 months BD holds the fiscal 2026 guide, the market starts valuing the stock off forward adjusted earnings rather than dirty trailing EPS, and the remaining authorization continues to shrink the float. High
Bottom Case 20% BDX $128.00 -11.4% 1 day to 9 months Litigation or remediation costs worsen, organic growth disappoints, or investors decide the post-spin simplification does not deserve any rerating. Medium
Invalidation / Stop Condition n/a Sustained break below BDX $132.00 n/a n/a Fresh evidence shows the raised guide is no longer credible, the clean-up charges are getting structurally worse, or capital return stalls. Medium

Probability-weighted expected value: approximately +9.5%, based on the scenario returns above.

Current market price / level: BDX $144.41.

Timestamp: 00:13 Singapore time on May 14, 2026.

Primary instrument: BDX common stock.

Alternative expressions considered: waiting for the ASR final settlement disclosure, or using long-dated call spreads. Waiting was rejected because part of the optical gap may close before then. Options were rejected as primary because I did not verify a live chain with tight spreads and acceptable open interest.

Confidence: Medium.

What Could Go Wrong

The strongest counterargument is straightforward: the market may be right that BD deserves a discount because the clean-up is not actually clean.

If product-remediation costs, legal costs, or portfolio dis-synergies keep bleeding into reported results, the stock can stay cheap or get cheaper. The company also still has exposure to execution risk in a simpler but not yet fully normalized operating model. This is not a balance-sheet panic, but it is still a situation where the market can insist on proof for longer than a valuation-driven investor would like.

What Would Prove This Wrong

The thesis fails if the company stops moving toward a cleaner earnings base.

A sustained move below $132.00 on fresh evidence that the raised fiscal 2026 guide is too high, that litigation or remediation costs are structurally worsening, or that the board has slowed the capital-return path would tell you the market is not merely slow. It would tell you the market is seeing a real impairment.

Bottom Line

BD no longer deserves to be read as a messy transition stub. The current company is simpler, the share count is falling, and management just raised the forward guide. The stock still looks like dirty trailing EPS. That is the disagreement inside the price.

Best trade strategy: Long BDX common stock. Options are secondary only if a live chain is later verified and priced well.

Sources